Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
COVID-19
Hodgkin lymphoma
Infection
Prophylaxis
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
23
11
2021
accepted:
28
01
2022
pubmed:
20
2
2022
medline:
3
8
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
Evidence on the effect of self-protection via social distancing and wearing face-masks on infections during chemotherapy is currently not available. We asked if the occurrence of acute infections during chemotherapy for advanced-stage Hodgkin lymphoma (HL) decreased when COVID-19 protection measures were in effect. We analyzed the occurrence of infections during all documented eBEACOPP cycles starting between 01 March and 30 June of 2017 to 2020 in patients treated within the GHSG HD21 study in Germany and compared the infection rates and characteristics by logistic regression models and means of descriptive statistics. We analyzed 911 cycles of 313 adult patients treated with 4 to 6 cycles of eBEACOPP. We found a significant decrease in the occurrence of infections during chemotherapy for HL during COVID-19 lockdown from 131 (19.6%) of 670 cycles in 2017-2019 to 30 (12.6%) of 239 cycles during COVID-19 lockdown [OR 0.574 (95% CI 0.354-0.930), P = 0.024]. The strongest effect was evident for unspecified infections with 39 cycles (5.8%) during 2017-2019 in comparison to 5 cycles (2.1%) during COVID-19 lockdown. 20 (24.1%) of 83 patients had an infection during the COVID-19 lockdown versus 99 (43.2%) of 229 patients in the years 2017-2019 (P = 0.0023). The significant decrease of infections during chemotherapy for HL during COVID-19 lockdown reveals the protective measures' potential to shield patients from transmissible pathogens. We conclude that these measures could be recommended for HL patients at risk for infections during chemotherapy.
Identifiants
pubmed: 35182355
doi: 10.1007/s15010-022-01765-3
pii: 10.1007/s15010-022-01765-3
pmc: PMC8857743
doi:
Substances chimiques
Bleomycin
11056-06-7
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
925-932Informations de copyright
© 2022. The Author(s).
Références
Cochrane Database Syst Rev. 2012 Jan 18;1:CD004386
pubmed: 22258955
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
J Natl Compr Canc Netw. 2016 Jul;14(7):882-913
pubmed: 27407129
Nat Clin Pract Oncol. 2008 Sep;5(9):543-56
pubmed: 18679394
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30355759
Infect Dis Health. 2020 Feb;25(1):22-29
pubmed: 31586572
BMJ. 2020 May 4;369:m1628
pubmed: 32366507
Hemasphere. 2017 Dec 20;1(1):e5
pubmed: 31723734
J Clin Oncol. 2018 Oct 20;36(30):3043-3054
pubmed: 30179565
Expert Rev Hematol. 2020 Aug;13(8):907-922
pubmed: 32749937
J Infect Public Health. 2019 May - Jun;12(3):364-366
pubmed: 30594483
N Engl J Med. 2003 Jun 12;348(24):2386-95
pubmed: 12802024
Cancer. 2006 May 15;106(10):2258-66
pubmed: 16575919
J Clin Oncol. 2015 Feb 10;33(5):465-71
pubmed: 25559804